

ORIGINAL PAPERS

Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis

María Ortiz-Lucas¹, Aurelio Tobias², Pablo Saz³ and Juan José Sebastián⁴

¹Bachelor Degree in Biochemistry. School of Health Sciences. Universidad de San Jorge. Zaragoza, Spain. ²Institute of Environmental Assessment and Water Research (IDAEA). Spanish Council for Scientific Research (CSIC). Barcelona, Spain. ³School of Medicine. Universidad de Zaragoza. Zaragoza, Spain. ⁴Department of Gastroenterology. Hospital Royo Villanova. Zaragoza, Spain

ABSTRACT

Background and objectives: immune system alteration in irritable bowel syndrome (IBS) patients may be modulated by probiotics. We assessed the efficacy of some probiotic species in alleviating characteristic IBS symptoms.

Material and methods: a meta-analysis of all identified randomized controlled trials comparing probiotics with placebo in treating IBS symptoms was performed with continuous data summarized using standardized mean differences (SMDs) with 95% confidence intervals (95% CIs), where appropriate. The random-effects model was employed in cases of heterogeneity; otherwise, fixed-effects models were used.

Results: meta-analysis was performed with 10 of 24 studies identified as suitable for inclusion. Probiotics improved pain scores if they contained *Bifidobacterium breve* (SMD, -0.34; 95% CI, -0.66; -0.02), *Bifidobacterium longum* (SMD, -0.48; 95% CI, -0.91; -0.06), or *Lactobacillus acidophilus* (SMD, -0.31; 95% CI, -0.61; -0.01) species. Distension scores were improved by probiotics containing *B. breve* (SMD, -0.45; 95% CI, -0.77; -0.13), *Bifidobacterium infantis*, *Lactobacillus casei*, or *Lactobacillus plantarum* (SMD, -0.53; 95% CI, -1.00; -0.06) species. All probiotic species tested improved flatulence: *B. breve* (SMD, -0.42; 95% CI, -0.75; -0.10), *B. infantis*, *L. casei*, *L. plantarum* (SMD, -0.60; 95% CI, -1.07; -0.13), *B. longum*, *L. acidophilus*, *Lactobacillus bulgaricus*, and *Streptococcus salivarius ssp. thermophilus* (SMD, -0.61; 95% CI, -1.01; -0.21). There was not a clear positive effect of probiotics concerning the quality of life.

Conclusions: some probiotics are an effective therapeutic option for IBS patients, and the effects on each IBS symptom are likely species-specific. Future studies must focus on the role of probiotics in modulating intestinal microbiota and the immune system while considering individual patient symptom profiles.

Key words: Probiotics. Irritable bowel syndrome. Immune system. Meta-analysis.

Received: 03-09-2012
Accepted: 28-01-2013

Correspondence: María Ortiz Lucas. School of Medicine. Universidad de San Jorge. Autovía A-23 Zaragoza-Huesca, km. 299. 50830 Villanueva de Gállego. Zaragoza, Spain
e-mail: mariaortizlucas@gmail.com

ABBREVIATIONS

C: Constipation.
CG: Control group.
CI: Confidence interval.
D: Diarrhea.
IBS: Irritable bowel syndrome.
QOL: Quality of life.
SD: Standard deviation.
SMD: Standardised mean differences.
TG: Treatment group.

INTRODUCTION

Defining and treating irritable bowel syndrome (IBS) can be challenging. Among the wide variety of treatment options, probiotics appear to be one of the best options (1). Recently, growing evidence has suggested an alteration in the immune system cell profile of IBS patients and a close relationship between the immune and nervous systems (2,3). Furthermore, several authors have studied the relationship between probiotic intake and blood cytokine levels (4) or changes in fecal microbiota (5,6).

Several reviews and meta-analyses that have evaluated the role of probiotics in IBS therapy have concluded that probiotics appear to improve overall IBS symptoms (7-12). However, a meta-analysis that includes any probiotic in the evaluation of symptom relief may not be the best method for assessing the efficacy of specific probiotics (11-13). Therefore, we assessed the efficacy of each specific probiotic species in alleviating characteristic IBS symptoms.

Ortiz-Lucas M, Tobias A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. *Rev Esp Enferm Dig* 2013;105:19-36.

METHODS

Study selection

A deep search of the PubMed, Cochrane Library, and EMBASE databases was performed for randomized controlled trials published up until January 31, 2012. An open search was conducted using the MeSH search terms "Probiotics" and "Irritable Bowel Syndrome". If a study could not be included/excluded based on the Title/Abstract field, the full text of the article was reviewed. Furthermore, the reference lists of studies that met inclusion criteria, pertinent review articles, and meta-analyses (7-12) were sought manually to identify additional relevant publications.

Selection criteria

Randomized controlled trials meeting all of the following criteria were included:

- Comparison of the efficacy of any probiotic therapy versus placebo for patients with IBS. Both groups had to be treated equally with the exception of the probiotic therapy.
- Rome criteria I, II, or III for the diagnosis of IBS.
- Subjects were adult patients (age \geq 18 years).
- Study results were published in English or Spanish.

Exclusion criteria

- Studies evaluating the efficacy of a symbiotic or a prebiotic.
- Additional therapy provided to both groups (e.g., drugs).
- Crossover studies.
- Studies including pathologies other than IBS.
- Congress abstracts.

Rules for selection among several effect estimates

Many of the studies selected for this meta-analysis reported more than 1 estimated effect of the results. Each result was analyzed by grouping studies with the same result measurement and making comparisons among them for each of the probiotic species. Evaluated symptoms included abdominal pain or discomfort, bloating or distension, stool frequency, stool consistency, flatulence, straining at stool, incomplete evacuation, fecal urgency, and IBS quality of life (QOL).

Investigators provided patients with a probiotic strain mixture in most studies. Considering this fact, and to analyze the possible effect of each probiotic individually, data were collected for a probiotic species if the study contained the species listed below, regardless of whether it contained other species. The following probiotic species were evaluated: *Bacillus coagulans*, *Bifidobacterium animalis ssp.*

lactis and *ssp. animalis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium infantis*, *Bifidobacterium longum*, *Lactobacillus acidophilus*, *Lactobacillus brevis*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus paracasei ssp. paracasei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus salivarius ssp. salivarius*, *Lactobacillus suntoyeyus ssp. HY780I*, *Lactococcus lactis*, *Propionibacterium freudenreichii ssp. shermanii*, *Saccharomyces boulardii*, and *Streptococcus salivarius ssp. thermophilus*.

Data extraction and quality assessment

Information regarding characteristics, outcome assessment and reporting, and adverse study effects was abstracted for each study that was selected for review. The Jadad scale was employed to assess the methodological quality of the retrieved studies (14). This scale adds single scoring points when the study is described as randomized, when it is described as double blind, and when a description of withdrawals and dropouts is present. A description and adequate method of randomization or a description and adequate method of blinding each result in the addition of 2 points. A score of 4 or more points indicated a well-designed study.

Statistical analysis

Sample size and mean and standard deviation (SD) data for each group [treatment group (TG) and control group (CG)] were collected as summary statistics at the end of the treatment period. Data were combined using standardized mean differences (SMD) because different scales were used in the studies to evaluate the effect of probiotics on each symptom. Heterogeneity between studies was assessed using Cochran's Q test, and the I^2 index was used to quantify the amount of heterogeneity, with a value greater than 50% indicating substantial heterogeneity (15,16). The study-specific SMDs were weighted by the inverse of their variance to compute a pooled mean difference and its 95% confidence interval (CI) using a random-effects model in cases of heterogeneity (17); otherwise, fixed-effects models were used. All analyses were performed using the Stata (18) 12.0 software (Stata Corporation, College Station, TX, USA).

RESULTS

The literature searches yielded 252 publications, 37 of which were considered potentially relevant and were retrieved (4-6,19-52). Of these, 24 studies were judged to meet the inclusion criteria (Fig. 1) (4-6,19-39). Table I contains a list of excluded studies and the reason for exclusion (40-52).

Data for the meta-analysis were extracted from 10 studies (19,20,25,29,31,32,34,36,37,39). The other 14 studies were not suitable for meta-analysis.




Fig. 1. Summary of the study selection and exclusion processes.

Study quality

The quality of the studies evaluated in this review was high, with only 6 (25%) having a punctuation lower than 4 (Table II). Items where criteria for a quality indicator were not all fulfilled or could not be evaluated for the majority of studies were “description and adequate method of randomization” and “withdrawals and dropouts”, with a total punctuation of 11/24 and 14/24 points, respectively.

From the 10 articles retrieved for the meta-analysis, 3 (30%) had a punctuation lower than 4 (studies highlighted in italics in table II).

Study characteristics

The characteristics of the studies included in the review are summarized in table III. This table provides information regarding participants, interventions, and main outcomes. The treatment phase lasted between 4 and 8 weeks in most studies, with the exception of 3 that lasted 5 (5) and 6 months (37,38).

Table I. Studies excluded from the review and the reason for exclusion

Reason for exclusion	Reference
Other criteria than Rome criteria for diagnosis/diagnostic criteria not clearly stated	Enck et al., 2009 (40) Enck et al., 2008 (41) Moon et al., 2007 (43) Enck et al., 2007 (44) Niedzielin et al., 2001 (50) Gade et al., 1989 (51) Maupas et al., 1983 (52)
No comparison of the efficacy between groups	Kajander et al., 2007 (42)
Not a randomized controlled trial	Kajander et al., 2006 (47)
Not statistical analysis of the results	Saggiaro, 2004 (49)
Congress abstract	Holowacz, 2007 (45) Simren, 2007 (46) Simren, 2006 (48)

Adverse events

The presence of adverse effects was mentioned in all but 6 studies (6,19-21,32,37). Reported adverse effects were few and were not serious. Additionally, the number of adverse events was similar in the TG and CG.

IBS symptoms

The most common symptoms studied in the randomized controlled trials accepted for review were abdominal pain or discomfort, bloating or distension, stool frequency, stool consistency, flatulence, straining during stool evacuation, incomplete evacuation, fecal urgency, and QOL.

The meta-analysis results are shown in table IV. The results for each IBS symptom evaluated are described according to the presence of a specific probiotic species.

Abdominal pain or discomfort

All retrieved studies evaluated the effects of probiotics on pain (4-6,19-39). The meta-analysis revealed a significant effect of probiotics in improving pain scores in probiotics containing *B. breve*, *B. longum*, or *L. acidophilus* species (25,29,31,32,34,36,37,39) and an almost significant effect for *S. salivarius ssp. thermophilus* species (25,29,31,32,34,36,39). *B. animalis*, *B. infantis*, *L. casei*, *L. plantarum*, *L. bulgaricus*, and *S. boulardii* species did not significantly improve pain (19,20,25,31,34,36,39).

Significant pain alleviation was not found in 16 studies (6,19,20,22-26,29,32,34,36-39), although a pain alleviation trend was found in 4 studies (5,23,32,37). Both the TG and

Table II. Methodological quality assessment of randomized trials (Jadad Scale)

Reference	Randomization	Description and adequate method of randomization	Double blinding	Description and adequate method of randomization	Withdrawals and dropouts	Total score
<i>Kabir, 2011 (19)</i>	Yes	No	Yes	Yes	No	3
<i>Choi, 2011 (20)</i>	Yes	Yes	Yes	Yes	No	4
Guglielmetti, 2011 (21)	Yes	Yes	Yes	Yes	Yes	5
Hong, 2011 (22)	Yes	No	Yes	Yes	Yes	4
Sondergaard, 2011 (23)	Yes	Yes	Yes	Yes	No	4
Michail, 2011 (24)	Yes	Yes	Yes	Yes	No	4
<i>Símren, 2010 (25)</i>	Yes	Yes	Yes	Yes	No	4
Dolin, 2009 (26)	Yes	No	Yes	Yes	No	3
Hun, 2009 (27)	Yes	No	Yes	No	No	2
Kyoung, 2009 (28)	Yes	Yes	Yes	Yes	Yes	5
<i>Williams, 2009 (29)</i>	Yes	No	Yes	Yes	Yes	4
Agrawal, 2009 (30)	Yes	No	Yes	Yes	No	3
<i>Zeng, 2008 (31)</i>	Yes	No	No	No	Yes	2
<i>Drouault-Holowacz, 2008 (32)</i>	Yes	Yes	Yes	Yes	Yes	5
Sinn, 2008 (33)	Yes	Yes	Yes	Yes	Yes	5
Kajander, 2008 (5)	Yes	Yes	Yes	Yes	Yes	5
<i>Guyonnet, 2007 (34)</i>	Yes	No	Yes	Yes	Yes	4
Whorwell, 2006 (35)	Yes	No	Yes	Yes	Yes	4
<i>Kim, 2005 (36)</i>	Yes	No	Yes	Yes	No	2
<i>Kajander, 2005 (37)</i>	Yes	Yes	Yes	Yes	Yes	5
Niv, 2005 (38)	Yes	No	Yes	Yes	Yes	4
O'Mahony, 2005 (4)	Yes	Yes	Yes	Yes	No	4
<i>Kim, 2003 (39)</i>	Yes	No	Yes	Yes	Yes	4
Nobaek, 2000 (6)	Yes	No	Yes	Yes	Yes	4

Italics type indicates studies included in the meta-analysis

CG improved during the intervention in 5 studies that reported data analyzing individual pain improvement for each of the groups before and after the study (6,24,25,29,34), with the exception of 1 study in which the TG improved but not the CG (24).

Probiotics significantly improved pain in 6 studies (4,21,28,30,33,35), 2 of which provided data of individual pain improvement for each of the groups before and after the study period. These 2 studies both showed improvement for the TG (21,33) and 1 showed improvement for the CG (21). Whorwell et al. (35) found a statistically significant pain reduction in a subgroup of patients with constipation (C-IBS) compared to the CG.

Two studies only provided data of the improvement for each of the groups before and after the study period (27,31). Both showed a significant improvement in the TG and 1 showed a significant improvement in the CG (27).

Abdominal bloating or distension

Eighteen studies evaluated the effects of probiotics on distension (4,5,19-25,27,29-31,34-37,39). The meta-analy-

sis revealed that probiotics significantly improved distension scores if they contained *B. breve*, *B. infantis*, *L. casei*, or *L. plantarum* species (36,37,39). *B. animalis*, *B. longum*, *L. acidophilus*, *S. boulardii*, *L. bulgaricus*, or *S. salivarius ssp. thermophilus* species did not significantly affect distension (19,20,25,29,31,34,36,39).

Distension was not significantly improved in 13 studies (4,19,20,22-25,29,30,34,36,37,39), although 5 studies, showed a trend toward improvement (23,30,36,37,39). Of these 13 studies, 5 reported the data by analyzing individual distension improvement for each of the groups before and after the study (24,25,29,34,39). Both the TG and CG improved during the intervention in these studies, with the exception of 2 studies in which the TG improved but not the CG (24,39).

Probiotics significantly improved distension in 3 studies (5,21,35). Whorwell et al. (35) found a trend of decreased distension in the subgroup of patients with diarrhea (D-IBS) compared to the CG.

Two studies only provided data on the improvement for each of the groups before and after the study period (27,31), both of which showed a significant improvement in the TG and CG.

Table III. Characteristics of the studies included in the review

Reference	Diagnostic criteria Number of patients		Probiotic and dosis	Treatment duration	Outcomes
	Probiotic n (Age range or Age mean SD; Sex F/M)	Placebo n (Age range or Age mean SD; Sex F/M)			
Kabir, 2011 (19)	Rome II n = 70 TG: 35 (mean age: 32.4 SD 11.08 yr; F/M: 3/32)		<i>S. boulardii</i> 250 mg Twice a day	Run in period: 0 wk Treatment period: 30 days Follow up period: 30 days	No effects on any of the studied items
Choi, 2011 (20)	Rome II n = 90 D-IBS, A-IBS Dropped out: 23; TG: 11, CG: 12 TG: 45 (mean age: 40.6 SD 13.1 yr; F/M: 17/18; D: 25(71.4%), A: 10(28.6%))		<i>S. boulardii</i> 2 x 10 ¹¹ cfu Twice a day	Run in period: 1 wk Treatment period: 4 wk Follow up period: 0 wk	Significant percentage improvement resulting from probiotics in IBSQOL. Significant improvement in the probiotics group when compared from the baseline for abdominal discomfort, mucus in stools, and passage of gas
Guglielmetti, 2011 (21)	Rome III n = 122 Dropped out: 3; TG: 1, CG: 2 TG: 60 (mean age: 36.65 SD 12.42 yr; F/M: 41/19; D: 14(23%), C: 9(15%), A: 37(62%))		<i>B. bifidum</i> MIMb75 1 x 10 ⁹ cfu	Run in period: 2 wk Treatment period: 4 wk Follow up period: 2 wk	Significant improvement resulting from probiotics for subjects' global assessments of IBS symptoms, abdominal pain/discomfort, distension/boating, urgency, the composite symptom score (mean of abdominal pain/discomfort, distension/boating, and urgency), global assessment of efficacy (also at the end of the study), bowel movement satisfaction (also at the end of the study), Health Related Quality of Life Short Form 12, and treatment responders
Hong, 2011 (22)	Rome III n = 74 Dropped out: 1; TG: 0, CG: 1 TG: 37 (mean age: 33 yr; age range: 21-55 yr; F/M: 25/12)		<i>L. sp.</i> HY7801, <i>B. longum</i> HY8004, <i>L. brevis</i> HY7401 4 x 10 ⁹ cfu	Run in period: 0 Treatment period: 8 wk Follow up period: 0	Significant improvement resulting from probiotics for defecation, discomfort and sum of symptom scores. Significant decrease in the frequency of stools in the probiotics group. Increased lactate levels and decreased glucose levels after probiotic intake. Tyrosine levels in the sera of female patients were decreased after administration of probiotics

(continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Reference	Diagnostic criteria Number of patients	Probiotic n (Age range or Age mean SD; Sex F/M)	Placebo n (Age range or Age mean SD; Sex F/M)	Probiotic and dosis	Treatment duration	Outcomes
Sondergaard, 2011 (23)	Rome II n = 64 Dropped out: 12; TG: 5, CG: 6	TG: 27 (mean age: 53.9 yr; age range: 29-67 yr; F/M: 20/7)	CG: 25 (mean age: 48.5 yr; age range: 29-67 yr; F/M: 19/6)	<i>L. bulgaricus</i> , <i>S. thermophilus</i> , <i>L. paracasei</i> spp. <i>paracasei</i> F19, <i>L. acidophilus</i> La5, <i>B. lactis</i> Bb ¹² 7.5 e ¹⁰ cfu	Run in period: 2 wk Treatment period: 8 wk Follow up period: 8 wk	Improvement trend resulting from probiotics for abdominal pain, abdominal distension, satisfaction with bowel habits, and influence of IBS on the patient's life in general (no p data given)
Michail, 2011 (24)	Rome III n = 24 D-IBS Mean age: 21.8 SD 17 yr; F/M: 16/8			VSL#3: <i>B. longum</i> , <i>B. infantis</i> , <i>B. breve</i> , <i>L. acidophilus</i> , <i>L. casei</i> , <i>L. delbrueckii</i> ssp. <i>Bulgaricus</i> , <i>L. plantarum</i> , <i>S. salivarius</i> spp. <i>thermophilus</i> 9 x 10 ⁸ bacteria/day	Run in period: 0 Treatment period: 8 wk Follow up period: 0	Significant improvement in the probiotics group when compared from the baseline on abdominal pain, bloating, diarrhea, satiety, global Gastrointestinal Symptom Rating Scale-IBS score, and QOL
Simren, 2010 (25)	Rome II n = 74 Dropped out: 7; TG: 4, CG: 3	TG: 37 (mean age: 42 SD 15 yr; F/M: 26/11; D: 15(41%), C: 5(13%), A: 17(46%))	CG: 37 (mean age: 44 SD 16 yr; F/M: 26/11; D: 11(30%), C: 6(16%), A: 20(54%))	<i>L. bulgaricus</i> , <i>S. thermophilus</i> , <i>L. paracasei</i> spp. <i>paracasei</i> F ¹⁹ , <i>L. acidophilus</i> La5 <i>y B. lactis</i> Bb12 5 x 10 ⁷ cfu/ml 200 ml twice a day	Run in period: 2 wk Treatment period: 8 wk Follow up period: 8 wk	Significant improvement in the probiotics group when compared from the baseline on IBS-SSJ, pain frequency, pain severity, bloating, bowel habit dissatisfaction, and interference with daily life
Dolin, 2009 (26)	Rome III n = 55 D-IBS Dropped out: 3; TG: 0, CG: 3	TG: 26 (mean age: 52.3 SD 11.1 yr; age range: 30-67 yr; F/M: 19/7)	TG: 29 (mean age: 44.0 SD 17.9 yr; age range: 18-73 yr; F/M: 23/6)	<i>Bacillus coagulans</i> GBI-30 6086 2 x 10 ⁹ cfu	Run in period: 2 Treatment period: 8 wk Follow up period: 0	Significant decrease in frequency of stools in the probiotics group

(Continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Reference	Diagnostic criteria		Probiotic and dosis	Treatment duration	Outcomes
	Number of patients	Placebo			
	n (Age range or Age mean SD; Sex F/M)	n (Age range or Age mean SD; Sex F/M)			
Hun, 2009 (27)	Rome II n = 50 D-IBS Dropped out: 6 Mean age: 48.36 yr; age range: 23-70 yr; F/M: 41/9		<i>Bacillus coagulans</i> GBI-30 6086 8 x 10 ⁸ cfu	Run in period: 0 Treatment period: 8 wk Follow up period: 0	Significant improvement in the probiotics group when compared from the baseline for abdominal pain and bloating
Kyoung, 2009 (28)	Rome III n = 70 Dropped out: 2; TG: 1, CG: 1 TG: 36 (mean age: 36 SD 2 yr; age range: 21-69 yr; F/M: 11/25) CG: 34 (mean age: 38 SD 3 yr; age range: 22-72 yr; F/M: 12/22)		<i>B. bifidum</i> BGN4, <i>B. lactis</i> AD011, <i>L. acidophilus</i> AD031, <i>L. casei</i> S141 2 x 10 ⁶ Twice a day	Run in period: 1 wk Treatment period: 8 wk Follow up period: 0	Significant improvement resulting from probiotics for abdominal pain and at week 4 for defecation discomfort (laborious evacuation, tenesmus, and urgency). Improvement trend resulting from probiotics for the global score (pain + flatulence + discomfort) (p = 0.064)
Williams, 2009 (29)	Rome II n = 56 Dropped out: 4; TG: 0, CG: 4 TG: 28 (mean age: 40 SD 12 yr; F/M: 25/3) CG: 24 (mean age: 38 SD 11 yr; F/M: 20/4)		<i>L. acidophilus</i> CUL-60 (NCIMB 30157) and CUL-21 (NCIMB 30156), <i>B. bifidum</i> CUL-20 (NCIMB 30153), <i>B. lactis</i> CUL-34 (NCIMB 30172) 2.5 x 10 ¹⁰ cfu/capsule 1 capsule daily	Run in period: 0 Treatment period: 8 wk Follow up period: 2 wk	Significant improvement resulting from probiotics for days with pain at week 10, satisfaction with bowel habits at week 6, QOL at week 8, and the Symptom Severity Score at weeks 6 and 8. Significant improvement in the probiotics group and in the placebo group when compared from the baseline on abdominal pain, days with pain, abdominal distension, satisfaction with bowel habits, QOL, and Symptom Severity Score
Agrawal, 2009 (30)	Rome II n = 38 Dropped out: 4 TG: 17 (mean age: 42; age range: 24-69 yr) CG: 17 (mean age: 37; age range: 20-59 yr)		<i>B. lactis</i> DN-173 010 1.25 x 10 ¹⁰ cfu/pot <i>S. thermophilus</i> and <i>L. bulgaricus</i> : 1.2 x 10 ⁹ cfu/pot 2 pots daily	Run in period: 0 Treatment period: 27 days Follow up period: 8 days	Significant improvement resulting from probiotics for abdominal pain or discomfort, overall IBS symptom severity, and urgency. Improvement trend resulting from probiotics for bloating (p = 0.059), flatulence (p = 0.092), consistency of stools (p = 0.058), straining (p = 0.074), and feelings of incomplete evacuation (p = 0.091). Abdominal inductance plethysmography showed a significant improvement resulting from probiotics for percentage change in

(continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Diagnostic criteria Number of patients		Probiotic	Placebo	Probiotic and dosis	Treatment duration	Outcomes
Reference	n (Age range or Age mean SD; Sex F/M)	n (Age range or Age mean SD; Sex F/M)	n (Age range or Age mean SD; Sex F/M)			
Zeng, 2008 (31)	Rome II n = 30 D-IBS Dropped out: 1; TG: 1, CG: 0 TG: 14 (mean age: 44.6 SD 12.4 yr; F/M: 4/10)	CG: 15 (mean age: 45.8 SD 9.2 yr; F/M: 6/9)		<i>S. thermophilus</i> 1 x 10 ⁸ cfu/ml, <i>L. bulgaricus</i> 1 x 10 ⁷ cfu/ml, <i>L. acidophilus</i> 1 x 10 ⁷ cfu/ml, and <i>B.</i> <i>longum</i> 1 x 10 ⁷ cfu/ml 200 g	Run in period: 0 Treatment period: 4 wk Follow up period: 0	maximal distension, and an improvement trend on abdominal distension (p = 0.096) and abdominal bloating (p = 0.084). A significant improvement resulting from probiotics for oro-caecal, colonic, and right colonic transit time Significant improvement in the probiotics group when compared from the baseline on the GSRQ questionnaire for gastrointestinal symptoms, abdominal pain, abdominal bloating, sensation of flatulence, and small bowel permeability
Drouault-Holowacz, 2008 (32)	Rome II n = 106 Dropped out: 6; TG: 5, CG: 1 TG: 48 (mean age: 47 SD 14 yr; F/M: 40/8; D: 29.2%, C: 25%, A: 45.8%)	CG: 52 (mean age: 44 SD 14.0 yr; F/M: 36/16; D: 28.8%, C: 32.7%, A: 36.5%, not determined: 1.9%)		<i>B. longum</i> LA 101 (29%), <i>Lb. acidophilus</i> LA 102 (29%), <i>L. lactis</i> LA 103 (29%) and <i>S. thermophilus</i> LA 104 (13%) 1 x 10 ¹⁰ cfu	Run in period: 0 Treatment period: 4 wk Follow up period: 0	Significant improvement resulting from probiotics in A-IBS patients on abdominal pain and a significant increase in C-IBS patients on stool frequency at weeks 1, 2, and 3, but not at week 4. Improvement trend from probiotics on abdominal pain (p = 0.054). Significant improvement resulting from probiotics for flatulence, waking during the night because of abdominal pain, and the need to loosen the belt or lie down after meal items
Sinn, 2008 (33)	Rome III n = 40 Dropped out: 0 TG: 20 (mean age: 41.9 SD 14.4 yr; F/M: 14/6; D: 1 (5%), C: 6 (30%), A: 13 (65%))	CG: 20 (mean age: 47.5 SD 11.0 yr; F/M: 12/8; D: 3 (15%), C: 5 (25%), A: 12 (60%))		<i>L. acidophilus</i> -SDC 2012 and 2013 2 x 10 ⁹ cfu/ml	Run in period: 0 Treatment period: 8 wk Follow up period: 0	Significant improvement in the probiotics group in abdominal pain or discomfort, abdominal pain or discomfort proportion, proportion of bowel habit satisfaction, proportion of straining during stool evacuation, and proportion of sense of incomplete evacuation. Significant improvement in the probiotics group when compared from the baseline for abdominal pain or discomfort, bowel habit satisfaction, straining at stool, and sense of incomplete evacuation. Significant improvement in the placebo group when compared from the baseline for sense of incomplete evacuation

(Continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Reference	Diagnostic criteria Number of patients		Probiotic and dosis	Treatment duration	Outcomes
	Probiotic n (Age range or Age mean SD; Sex F/M)	Placebo n (Age range or Age mean SD; Sex F/M)			
Kajander, 2008 (5)	Rome II n = 86 Dropped out: 15; TG: 5, CG: 10		<i>L. rhamnosus</i> GG (ATCC 53103, LGG), <i>L. rhamnosus</i> Lc705 (DSM 7061), <i>P. freudenreichii</i> ssp. <i>shermanii</i> JS (DSM 7067), <i>B. animalis</i> ssp. <i>lactis</i> Bb12 (DSM 15954) 1 x 10 ⁷ cfu/ml 1.2 dl. daily	Run in period: 3 wk Treatment period: 5 month Follow up period: 3 wk	Significant improvement in the probiotics group for distension and overall score (pain + distension + flatulence + borborygmi). Improvement trend resulting from probiotic use for abdominal pain (p = 0.052), flatulence (p = 0.11), and borborygmi (p = 0.086). The health-related QOL questionnaire found a significant improvement resulting from probiotic use for bowel symptoms and an improvement trend for fatigue. A significant stabilization of the microbiota was found in the probiotics group but not in the placebo group
Guyonnet, 2007 (34)	Rome II n = 274 C-IBS Dropped out: 7; TG: 5, CG: 2	TG: 135 (mean age: 49.4 SD 11.4 yr; age range: 23-65 yr; F/M: 106/29)	<i>B. animalis</i> DN-173 010: 1.25 x 10 ¹⁰ cfu/pot <i>S. thermophilus</i> and <i>L. bulgaricus</i> : 1.2 x 10 ¹⁰ cfu/pot 2 pots daily	Run in period: 1-3 wk Treatment period: 6 wk Follow up period: 0	Significant increase in stool frequency in a subgroup of patients with < 3 stools per week. Significant improvement in the probiotics group and in the placebo group when compared from the baseline on bloating and abdominal pain. Significant improvement in the probiotics group for discomfort, daily activities, anxiety, diet, sleep, coping with the disease, and global score. Significant improvement in the placebo group for discomfort, daily activities, anxiety, diet, sleep, coping with the disease, impact of stress, and global score
Whorwell, 2006 (35)	Rome II n = 325 Dropped out: 32; TG1: 7; TG2: 7; TG1: 6; CG: 12	TG1: 90 (mean age: 41.8 SD 1.10 yr; age range: 22-63 yr; F/M: 90/0)	<i>B. infantis</i> 35624 TG1: 1 x 10 ¹⁰ live bacterial cells in a capsule TG2: 1 x 10 ⁸ live bacterial cells in a capsule TG3: 1 x 10 ⁶ live bacterial cells in a capsule	Run in period: 2 wk Treatment period: 4 wk Follow up period: 2 wk	Significant improvement resulting from probiotic use (TG2) for abdominal pain and discomfort, bloating and distension, sense of incomplete evacuation, straining during stool evacuation, passage of gas, bowel habit satisfaction, overall assessment of IBS symptoms, the composite score (abdominal pain/discomfort + bloating + bowel habit satisfaction), and subjects' global assessment of relief from IBS symptoms. Improvement trend resulting from probiotic use (TG2) for urgency of bowel movement (p = 0.09). No difference in the frequency of stools (TG2) for the 50 th baseline percentile, but a significant difference in TG2 vs. CG below the 15 th and above

(Continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Reference	Diagnostic criteria Number of patients	Probiotic n (Age range or Age mean SD; Sex F/M)	Placebo n (Age range or Age mean SD; Sex F/M)	Probiotic and dosis	Treatment duration	Outcomes
Kim, 2005 (36)	Rome II n = 48 TG: 24 (mean age: 40 SD 3 yr; age range: 22-73 yr; F/M: 21/3)	CG: 24 (mean age: 46 SD 3 yr; age range: 21-75 yr; F/M: 24/0)	VSL#3: <i>B. longum</i> , <i>B. infantis</i> , <i>B. breve</i> , <i>L. acidophilus</i> , <i>L. casei</i> , <i>L. delbrueckii</i> ssp. <i>Bulgarius</i> , <i>L. plantarum</i> , <i>S. salivarius</i> ssp. <i>thermophilus</i> 450 billion lyophilized bacteria	Run in period: 0 Treatment period: - 17 subjects: 8 wk - 31 subjects: 4 wk Follow up period: 0	the 81 st percentiles, resulting in a normalization of bowel habits. Significant improvement resulting from probiotic use (TG3) for consistency of stools (softer stool form) Significant improvement resulting from probiotic use on the sensation of flatulence. Colonic transit was significantly retarded in the probiotic group vs. the placebo group. Improvement trend resulting from probiotic use for abdominal bloating (p = 0.11)	
Kajander, 2005 (37)	Rome II n = 54 Dropped out: 15; TG: 6; CG: 9 TG: 52 (mean age: 46 yr; age range: 23-65 yr; F/M: 39/13; D: 26 (50%), C: 11 (21%), A: 15 (29%))	CG: 51 (mean age: 45 yr; age range: 21-65 yr; F/M: 40/11; D: 23 (45%), C: 13 (25%), A: 15 (29%))	<i>L. rhamnosus</i> GG, <i>L. rhamnosus</i> LC705, <i>B. breve</i> Bb99, <i>P. freudenreichii</i> ssp. <i>Shermanii</i> JS 8-9 x 10 ⁸ cfu/day	Run in period: 1 wk Treatment period: 6 months Follow up period: 0	Significant improvement resulting from probiotic use for borborygmi, overall score (pain + distension + flatulence + borborygmi), urgency, and the feeling of incomplete evacuation. Improvement trend resulting from probiotic use on abdominal pain (p = 0.110) and distension (p = 0.083). Overall increased trend in the frequency of stools in the probiotic group vs. the placebo group (p = 0.102) and in the A-IBS subgroup (p = 0.076). Improvement trend in the consistency of stools in the C-IBS subgroup (p = 0.067)	
Niv, 2005 (38)	Rome II n = 54 Dropped out: 15; TG: 6; CG: 9 TG: 27 (mean age: 45.7 SD 14.2 yr; F/M: 20/7)	CG: 27 (mean age: 45.6 SD 16.1 yr; F/M: 16/11)	<i>L. reuteri</i> ATCC 55730 5 x 10 ⁷ cfu First 7 days: 4 tablets/day After: 2 tablets/day	Run in period: 1-2 wk Treatment period: 6 months Follow up period: 0	Improvement trend resulting from probiotic use for constipation (p = 0.0714)	

(Continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Reference	Diagnostic criteria Number of patients	Probiotic n (Age range or Age mean SD; Sex F/M)	Placebo n (Age range or Age mean SD; Sex F/M)	Probiotic and dosis	Treatment duration	Outcomes
O'Mahony, 2005 (4)	Rome II n = 75 Dropped out in treatment period: 3 Dropped out in washout period: 5 Mean age: 44.3 yr; age range: 18-73 yr; FMI: 64%/36%; D: 28%, C: 26%, A: 45%			TG1: <i>L. salivarius</i> <i>spp. salivarius</i> UCC4331 TG2: <i>B. infantis</i> 35624 1 x 10 ¹⁰ live bacterial cells in a malted milk drink	Run in period: 4 wk Treatment period: 8 wk Follow up period: 4 wk	<i>Lactobacillus salivarius</i> Significant improvements from probiotics on abdominal pain or discomfort in weeks 2 and 7, and on the composite score in week 2. <i>Bifidobacterium infantis</i> Significant improvement resulting from probiotics for abdominal pain or discomfort at weeks 1, 2, 4, 5, and 7 and week 1 of the washout period, on bloating or distension at weeks 2, 5, and 6, on bowel movement difficulty or urgency at weeks 2, 3, 5 and 6 and week 1 of the washout period, and on the composite score at every week of the treatment period and weeks 1 and 4 of the washout period. Lower IBSQOL score (ns) from probiotics and a significant improvement on health worry. <i>L. salivarius</i> vs. <i>B. infantis</i> Significant improvement resulting from <i>B. infantis</i> for the composite score at weeks 2, 4, 6, and 8 and at weeks 3 of the 4 of the washout period on at least 1 of the scales (Likert or Visual Analogue Scale). BLOOD CYTOKINE LEVELS Cytokine levels returned to levels similar to those observed for a healthy volunteer group in the <i>B. infantis</i> group but not in the <i>L. salivarius</i> or placebo groups

(Continue on next page)

Table III. Characteristics of the studies included in the review (Continuation)

Reference	Diagnostic criteria Number of patients		Probiotic and dosis	Treatment duration	Outcomes
	Probiotic n (Age range or Age mean SD; Sex F/M)	Placebo n (Age range or Age mean SD; Sex F/M)			
Kim, 2003 (39)	Rome II n = 60 D-IBS Dropped out: 1; TG: 0; CG: 1 TG: 12 (mean age: 48 SD 5.7 yr; age range: 19-70 yr; F/M: 10/2)	CG: 13 (mean age: 38 SD 3.4 yr; age range: 19-59 yr; F/M: 8/5)	VSL#3: <i>B. longum</i> , <i>B. infantis</i> , <i>B. breve</i> , <i>L. acidophilus</i> , <i>L. casei</i> , <i>L. delibruceckii</i> <i>ssp. Bulgaricus</i> , <i>L. plantarum</i> , <i>S. salivarius ssp.</i> <i>thermophilus</i> 450 billion lyophilized bacteria per day in a powder form miscible in yoghurt or soluble in water (taken in two times)	Run in period: 2 wk Treatment period: 8 wk Follow up period: 0	Improvement trend from probiotics on bloating ($p = 0.09$). Significant improvement in the probiotics group when compared from the baseline for bloating
Nobaek, 2000 (6)	Rome I n = 60 Dropped out: 8; TG: 5; CG: 3 TG: 25 (mean age: 51 yr; age range: 24-78 yr; F/M: 16/9)	CG: 27 (mean age: 46 yr; age range: 21-66 yr; F/M: 20/7)	<i>L. plantarum</i> DSM 9843 (299v) and 0.009 g/ml oat flour 400 ml/day of a rose-hip drink 5 x 10 ⁷ cfu/ml	Run in period: 2 wk Treatment period: 4 wk Follow up period: 12 months	Significant improvement resulting from probiotics for the number of days with abundant gas production and flatulence. Improvement trend from probiotics on overall gastrointestinal function ($p = 0.06$) and defecation function ($p = 0.06$)

Table IV. Meta-analysis of the efficacy of probiotics species for treating IBS patients. The results refer to the presence of any probiotic species for treating each IBS symptom

Outcome	<i>n</i>	No. of patients	Overall estimates SMD (95% CI)	Heterogeneity <i>I</i> ² (Q;df;p)
PAIN				
<i>B. Animalis</i> (25,29,34)	3	393	-0.05 (-0.24; 0.15)	0.0 (0.1;2; 0.943)
<i>B. Breve</i> (36,37,39)	3	154	-0.34 (-0.66; -0.02)	0.0 (0.1;2; 0.943)
<i>B. Infantis</i> - <i>L. Casei</i> - <i>L. Plantarum</i> (36,39)	2	73	-0.31 (-0.77; 0.15)	0.0 (0.1;1; 0.763)
<i>B. Longum</i> (31,32,34,39)	4	202	-0.48 (-0.91; -0.06)	49.5 (5.9;3; 0.115)
<i>L. Acidophilus</i> (25,29,31,32,36,39)	6	328	-0.31 (-0.61; -0.01)	42.3 (8.7;5; 0.123)
<i>L. Bulgaricus</i> (25,31,34,36,39)	5	443	-0.31 (-0.67; 0.05)	59.4 (9.6;4; 0.043)
<i>S. Boulardii</i> (19,20)	2	137	0.18 (-0.16; 0.51)	0.0 (0.2;1; 0.652)
<i>S. Salivarius ssp. Thermophilus</i> (25,31,32,34,36,39)	6	543	-0.28 (-0.56; 0.00)	50.5 (10.1;5; 0.072)
DISTENSION				
<i>B. Animalis</i> (25,29,34)	3	393	0.00 (-0.20; 0.20)	0.0 (1.0;2; 0.612)
<i>B. Breve</i> (36,37,39)	3	154	-0.45 (-0.77; -0.13)	0.0 (0.3;2; 0.858)
<i>B. Infantis</i> - <i>L. Casei</i> - <i>L. Plantarum</i> (36,39)	2	73	-0.53 (-1.00; -0.06)	0.0 (0.1;1; 0.749)
<i>B. Longum</i> (31,36,39)	3	102	-0.19 (-0.90; 0.53)	67.6 (6.2;2; 0.046)
<i>L. Acidophilus</i> (25,29,31,36,39)	5	228	-0.17 (-0.51; 0.18)	38.2 (6.5;4; 0.167)
<i>S. Boulardii</i> (19,20)	2	137	-0.06 (-0.67; 0.55)	69.1 (3.2;1; 0.072)
<i>L. Bulgaricus</i> - <i>S. Salivarius ssp.</i> <i>Thermophilus</i> (25,31,32,34,39)	5	443	-0.08 (-0.39; 0.24)	49.7 (2.0;1; 0.159)
STOOL FREQUENCY				
<i>B. Breve</i> (36,37,39)	3	154	0.13 (-0.49; 0.74)	47.2 (7.6;4; 0.108)
<i>B. Infantis</i> - <i>B. Longum</i> - <i>L. Acidophilus</i> - <i>L. Bulgaricus</i> - <i>L. Casei</i> - <i>L. Plantarum</i> - <i>S. Salivarius ssp. Thermophilus</i> (36,39)	2	73	-0.27 (-0.73; 0.19)	0.0 (0.0;1; 0.966)
STOOL CONSISTENCY				
<i>B. Breve</i> - <i>B. Infantis</i> - <i>B. Longum</i> - <i>L. Acidophilus</i> - <i>L. Bulgaricus</i> - <i>L. Casei</i> - <i>L. Plantarum</i> - <i>S. Salivarius ssp.</i> <i>Thermophilus</i> (36,39)	2	73	-0.04 (-0.50; 0.42)	0.0 (1.0;1; 0.326)
FLATULENCE				
<i>B. Breve</i> (36,37,39)	3	154	-0.42 (-0.75; -0.10)	0.0 (1.9;2; 0.389)
<i>B. Infantis</i> - <i>L. Casei</i> - <i>L. Plantarum</i> (36,39)	2	73	-0.60 (-1.07; -0.13)	0.0 (0.9;1; 0.332)
<i>B. Longum</i> - <i>L. Acidophilus</i> - <i>L. Bulgaricus</i> - <i>S. Salivarius ssp.</i> <i>Thermophilus</i> (31,36,39)	3	102	-0.61 (-1.01; -0.21)	0.0 (1.0;2; 0.621)
STRAINING				
<i>B. Breve</i> - <i>B. Infantis</i> - <i>B. Longum</i> - <i>L. Acidophilus</i> - <i>L. Bulgaricus</i> - <i>L. Casei</i> - <i>L. Plantarum</i> - <i>S. Salivarius ssp.</i> <i>Thermophilus</i> (36,39)	2	73	0.45 (-0.16; 1.06)	36.7 (1.6;1; 0.209)
URGENCY				
<i>B. Breve</i> - <i>B. Infantis</i> - <i>B. Longum</i> - <i>L. Acidophilus</i> - <i>L. Bulgaricus</i> - <i>L. Casei</i> - <i>L. Plantarum</i> - <i>S. Salivarius ssp.</i> <i>Thermophilus</i> (36,39)	2	73	-0.29 (-0.75; 0.17)	0.0 (0.0;1; 0.986)

SMD: standardized mean differences; CI: confidence interval; *I*²: heterogeneity statistic; Q: Cochran s Q test; df: degrees of freedom; p: p-value. Italics indicates significance.

Stool frequency

Sixteen studies evaluated the effects of probiotics on stool frequency (4,6,19-22,26,28,30,32-37,39). Probiotics containing *B. breve*, *B. infantis*, *B. longum*, *L. acidophilus*, *L. bulgaricus*, *L. casei*, *L. plantarum*, or *S. salivarius ssp. thermophilus* species (36,37,39) did not improve frequency scores according to the meta-analysis.

Only 2 of 16 studies showed a significant decrease in the stool frequency (22,26). One study showed an increased trend in the stool frequency, which was also shown in the alternators IBS subgroup, but this tendency was not found in the D-IBS or C-IBS subgroup (37). Drouault-Holowacz et al. (32) found a significant increase in the stool frequency in a subgroup of patients with C-IBS at weeks 1, 2, and 3, but not at week 4, of probiotic consumption. Guyonnet et al. (34) found a significant increase in a subgroup of patients with less than 3 stools per week. Whorwell et al. (35) found a normalization of bowel habits in patients below the 15th and above the 81th stool frequency percentiles.

Stool consistency

Sixteen studies evaluated the effects of probiotics on stool consistency (4-6,19,20,22,26,28,30,32-37,39). Probiotics containing *B. breve*, *B. infantis*, *B. longum*, *L. acidophilus*, *L. bulgaricus*, *L. casei*, *L. plantarum*, or *S. salivarius ssp. thermophilus* species (36,39) did not significantly improve consistency scores according to the meta-analysis.

Although none of these studies showed a significant improvement on stool consistency, improvement trends were found by Agrawal et al. (30) and Whorwell et al. (35) in a group treated with 1×10^6 live bacterial cells. Nobaek et al. (6) found a significant decrease in the number of days with rather loose to very loose stools and a significant increase in the number of days with normal stools, but not in the number of days with rather hard to very hard stools.

Flatulence

Ten studies evaluated the effects of probiotics on flatulence (5,6,26,28,30-32,36,37,39). The meta-analysis found that all probiotic species studied: *B. breve*, *B. infantis*, *L. casei*, *L. plantarum*, *B. longum*, *L. acidophilus*, *L. bulgaricus*, and *S. salivarius ssp. thermophilus* (31,36,37,39) significantly improved flatulence scores.

Significant improvements in flatulence were not found in 6 studies (5,26,28,30,37,39), although 2 (5,30) showed a trend of improvement. Kajander et al. (37) found a significant improvement in flatulence in those patients in whom the symptom score had decreased.

Flatulence was significantly improved by probiotics in 3 studies (6,32,36). Individual flatulence improvement for the TG and CG was found before and after the study period in 1

study (6). Improvement in the TG but not the CG before and after the study period was found in another study (31).

Straining during stool evacuation

Seven studies evaluated the effects of probiotics on straining (20,30,33,35-37,39). Probiotics containing *B. breve*, *B. infantis*, *B. longum*, *L. acidophilus*, *L. bulgaricus*, *L. casei*, *L. plantarum*, or *S. salivarius ssp. thermophilus* species (36,39) did not significantly improve straining scores according to the meta-analysis.

Straining was not alleviated in 5 studies (20,30,36,37,39), but a trend toward improvement was found in 1 of these studies (30).

Probiotics significantly improved straining in the TG and a subgroup of patients with D-IBS compared to the CG in 1 study (35). Sinn et al. (33) found a significant decrease in straining when considering the percentage reduction of the symptom score and found an improvement in the TG, but not in the CG, when comparing data before and after the study period.

Sense of incomplete evacuation

Seven studies evaluated the effects of probiotics on the sense of incomplete evacuation (20,21,30,33,35-37), 3 of which did not show a significant improvement (20,21,36). One of these studies (20) showed an improvement in the TG, but not in the CG, when comparing data before and after the study.

Probiotics significantly improved the sense of incomplete evacuation in 4 studies (30,33,35,37). Sinn et al. (33) found a significant improvement when considering the percentage reduction of the symptom score and found a significant improvement in both the TG and CG when comparing data before and after the study period. Whorwell et al. (35) found an improvement in the subgroup of patients with D-IBS compared to the CG.

Fecal urgency

Nine studies evaluated the effects of probiotics on fecal urgency (4,20,21,26,30,35-37,39). Probiotics containing *B. breve*, *B. infantis*, *B. longum*, *L. acidophilus*, *L. bulgaricus*, *L. casei*, *L. plantarum*, or *S. salivarius ssp. thermophilus* (36,39) did not significantly improve fecal urgency according to the meta-analysis.

Fecal urgency was not significantly improved in 6 studies (4,20,26,35,36,39). One of these studies (35) found a trend for improved urgency and another (39) found an improvement in the TG, but not in the CG, when comparing data before and after the study period.

Probiotics significantly improved urgency in 4 studies (4,21,30,37). O'Mahony et al. (4) found this improvement

in the group treated with *B. infantis* at weeks 2, 3, 5, and 6 and at week 1 of the wash out period. This improvement was not observed in the group treated with *L. salivarius ssp. salivarius*. Whorwell et al. (35) found a trend of decreased fecal urgency in the subgroup of patients with D-IBS compared to the CG.

IBS QOL

Twelve studies evaluated the effects of probiotics on QOL (4,5,20,21,24-26,28,29,32,35,38), 7 of which did not find a significant improvement (24-26,28,32,35,38). One of these studies (24) found an improvement in the TG, but not in the CG, when comparing data before and after the study period.

Probiotics significantly improved QOL in 5 studies (4,5,20,21,29). Choi et al. (20) found a significant improvement in the percentage reduction of the symptom score and Williams et al. (29) found an improvement in the TG and CG when comparing data before and after the study period. Kajander et al. (5) showed a significant improvement in “bowel symptoms”, a trend for improved “fatigue”, but no effects on “activity limitations” and “emotional function” items. O’Mahony et al. (4) found lower IBS-QOL scores for *L. salivarius ssp. salivarius* and *B. infantis* for most domains, but they only showed significance for “health worry” in the *B. infantis* group and a trend of improved “dysphoria” in the *L. salivarius ssp. salivarius* group.

DISCUSSION

This review and meta-analysis provides additional evidence for the beneficial effect of probiotics in IBS treatment. Several authors found altered microbiota in IBS patients (53-57). Intestinal bacteria may play a significant role in inducing IBS because a change in the microbiota can lead to an activation of the immune system, which could explain symptom generation and the effects on the central nervous system (58-64). Probiotic intake may preserve the fecal microbiota (5), normalize the cytokine blood levels (4), improve the intestinal transit time (30), decrease the small intestine permeability (31), and alter the fermentation pattern reducing the small intestinal bacterial overgrowth (65) in these patients, but further research is required to confirm these results.

Although positive effects of probiotics were found in this review and meta-analysis, many studies have not found a significant effect. This may result from the significant improvements found in the TG and in CG when comparing data from the baseline in many of these studies, which is consistent with the placebo effect and with the fluctuating symptoms found in these patients (66-68).

The differences in these study results could also be attributable to the characteristics of the disease. Rome criteria provide a useful tool to diagnose IBS patients, but the subjectivity of quantifying IBS symptoms is a limitation when

studying the efficacy of a therapy (68-70). Additionally, these differences can be due to variations in study design, duration, IBS population, and probiotic dose and species. These factors make it difficult to compare the results of these studies.

Although other published reviews and meta-analyses have studied the effects of probiotics in IBS patients (7-12,71), our study evaluated the efficacy of probiotics on a wide variety of IBS symptoms. This allowed us to determine whether a specific probiotic species is beneficial for treating individual IBS symptoms. To our knowledge, only 1 other meta-analysis studied the effects of individual species on IBS treatment. The authors found no impact on symptoms in patients treated with *Lactobacilli* but found a significant improvement when patients were treated with probiotic combinations. They suggested that *Bifidobacteria* were the active ingredients in probiotic combinations because they found a non-significant improvement trend from *Bifidobacteria* for IBS symptoms (12).

The results of this meta-analysis corroborate the positive effects found for the treatment of pain in IBS patients in other meta-analyses (7,10,12). However, Hoveyda et al. found this improvement when considering dichotomous data but not continuous data (7) and McFarland et al. only considered dichotomous data in their analysis (10). Other reviews state that probiotics have a positive effect on abdominal pain, suggesting that this effect is species specific (11,71).

The different results found in other meta-analyses concerning the efficacy of probiotics in improving distension could be explained by the presence or absence of different probiotic species in the mixture, as shown in this meta-analysis (7,12). This is corroborated by other reviews (11,71).

We found that the presence of any probiotic species had a positive effect on flatulence. Other meta-analysis found a positive effect when considering any probiotic mixture (7,12). However, Hoveyda et al. (7) noted this improvement when considering dichotomous data but not when considering continuous data.

The effects of probiotics on the frequency or consistency of stools should be studied with caution because these factors vary in IBS patients. Some of the retrieved studies found that probiotics had a positive effect on the frequency of stools in D-IBS patients (24,26,35), while others did not (37,39). Similarly, positive (32,34,35) or negative (37) results were found for C-IBS patients. No effects on the consistency of stools have been shown in D-IBS and C-IBS subgroups (6,26,34,37,39), with the exception of Nobaek et al. (6) (see results) and a trend of improvement in C-IBS patients (37). Further analyses should be performed on the stool profiles of these patients.

In addition to the previously discussed factors, future studies should include aspects such as focusing probiotics treatment on patients with a predominance of gastrointestinal symptoms, obtaining the microbiological profile of patients (55), or considering the psychological profile of patients (72).

Although the absence of adverse effects is an additional advantage of probiotic therapy, clinicians should consider

the global state of the patient before prescribing them (13,60,72).

A study published after our meta-analysis found that a probiotic mixture containing *L. acidophilus* (KCTC 11906BP), *L. plantarum* (KCTC 11867BP), *L. rhamnosus* (KCTC 11868BP), *B. breve* (KCTC 11858BP), *Bifidobacterium lactis* (KCTC 11903BP), *B. longum* (KCTC 11860BP), and *Streptococcus thermophilus* (KCTC 11870BP) did not have a significant effect on abdominal pain or discomfort, distension, stool frequency, urgency, or QOL in D-IBS patients. A significant improvement in stool consistency was seen in the probiotic group (73).

This study has several limitations. Some of the meta-analyses included a small number of randomized controlled trials because many studies did not provide adequate data for performing a meta-analysis. Furthermore, because most studies investigated the effect of a probiotic mixture, we could not carry out our analysis for specific probiotic species and/or mixtures. Instead, the meta-analysis was performed according to the presence of a specific probiotic species; this can provide an estimate of the influence of each species in alleviating individual IBS symptoms. Additionally, the inclusion of many symptoms in the analysis can provide benefits that are more specific for the treatment of individual patients. Another strength of this study is that the meta-analysis was performed with continuous rather than dichotomous data.

These results may enable development of individualized probiotic mixtures for each patient according to the predominant symptoms in the not-so-distant future. This is particularly true in IBS subtypes with a predominance of abdominal pain or discomfort and/or declined QOL, or when there is a predominance of abdominal distension or severe fecal urgency. We doubt that a standard probiotic mixture can improve any IBS symptom profile. Therefore, a standard IBS therapy that can be administered to every patient may not be possible.

In conclusion, evidence suggests that probiotics are an effective treatment option for IBS patients and that the effects of probiotics on each IBS symptom are likely species-specific. Future research should focus more specifically on species, combinations, dose, duration, IBS subtypes, and IBS individual symptoms, while employing standardized measurement tools. Although probiotics are a safe therapy, clinicians should consider other concomitant pathologies when prescribing them to their patients.

Our *Research Group in Functional Digestive Disorders and Psychoimmunology*, which is within the framework of the Biomedical Research Map of the Aragon Institute of Health Sciences in Spain, is convinced that the key factors in IBS are the immune system and intestinal microbiota after a detailed review of the scientific evidence concerning IBS. Therefore, we think that IBS treatment should focus on both of these factors influencing intestinal dysbiosis by considering the effects of different probiotic species on the symptomatology of individual patients.

Finally, we anticipate that a better design and combination of probiotics will soon be available for the treatment of IBS and other pathologies involving intestinal and general immunity.

REFERENCES

1. Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2010;22:1402-11.
2. Ortiz Lucas M, Saz Peiró P, Sebastián Domingo JJ. Irritable bowel syndrome immune hypothesis. Part one: The role of lymphocytes and mast cells. *Rev Esp Enferm Dig* 2010;102:637-47.
3. Ortiz Lucas M, Saz Peiró P, Sebastián Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: The role of cytokines. *Rev Esp Enferm Dig* 2010;102:711-7.
4. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. *Gastroenterology* 2005;128:541-51.
5. Kajander K, Myllyluoma E, Rajili-Stojanovi M, Kyrönalo S, Rasmussen M, Järvenpää S, et al. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. *Aliment Pharmacol Ther* 2008;27:48-57.
6. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *Am J Gastroenterol* 2000;95:1231-8.
7. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome. *BMC Gastroenterol* 2009;9:15.
8. Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB. Effectiveness of probiotics in the treatment of irritable bowel syndrome. *Pharmacotherapy* 2008;28:496-505.
9. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: A meta-analysis of randomized, controlled trials. *Dis Colon Rectum* 2008;51:1775-80.
10. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World J Gastroenterol* 2008;14:2650-61.
11. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. *Am J Gastroenterol* 2009;104:1033-49.
12. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A, Brandt L, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. *Gut* 2010;59:325-32.
13. Rowland I, Capurso L, Collins K, Cummings J, Delzenne N, Goulet O, et al. Current level of consensus on probiotic science -report of an expert meeting-London, 23 November 2009. *Gut Microbes* 2010;1:436-9.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials* 1996;17:1-12.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-88.
18. Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. Metan: Fixed- and random-effects meta-analysis. *Stata Journal* 2009;8:3-28.
19. Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M. Role of *Saccharomyces Boulardii* in diarrhea predominant irritable bowel syndrome. *Mymensingh Med J* 2011;20:397-401.
20. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of *saccharomyces boulardii* in irritable bowel syndrome: effect on quality of life. *J Clin Gastroenterol* 2011;45:679-83.
21. Guglielmetti S, Mora D, Gschwendner M, Popp K. Randomised clinical trial: *Bifidobacterium bifidum* MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life -A double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2011;33:1123-32.

22. Hong YS, Hong KS, Park MH, Ahn YT, Lee JH, Huh CS, et al. Meta-bonomic understanding of probiotic effects in humans with irritable bowel syndrome. *J Clin Gastroenterol* 2011;45:415-25.
23. Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesho R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. *Scand J Gastroenterol* 2011;46:663-72.
24. Michail S, Henche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. *Probiotics Antimicrob Proteins* 2011;3:1-7.
25. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – A randomized, double-blind, controlled study. *Aliment Pharmacol Ther* 2010;31:218-27.
26. Dolin BJ. Effects of a proprietary *Bacillus coagulans* preparation on symptoms of diarrhea-predominant irritable bowel syndrome. *Methods Find Exp Clin Pharmacol* 2009;31:655-9.
27. Hun L. *Bacillus coagulans* significantly improved abdominal pain and bloating in patients with IBS. *Postgrad Med* 2009;121:119-24.
28. Kyoung SH, Hyoun WK, Jong PI, Geun EJ, Sang GK, Hyun CJ, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. *Gut Liver* 2009;3:101-7.
29. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, et al. Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. *Aliment Pharmacol Ther* 2009;29:97-103.
30. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Fevillerat N, et al. Clinical trial: The effects of a fermented milk product containing *Bifidobacterium lactis* DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. *Aliment Pharmacol Ther* 2009;29:104-14.
31. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther* 2008;28:994-1002.
32. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. *Gastroenterol Clin Biol* 2008;32:147-52.
33. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al. Therapeutic effect of *Lactobacillus acidophilus*-SDC 2012, 2013 in patients with irritable bowel syndrome. *Dig Dis Sci* 2008;53:2714-8.
34. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing *Bifidobacterium animalis* DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. *Aliment Pharmacol Ther* 2007;26:475-86.
35. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic *Bifidobacterium infantis* 35624 in women with irritable bowel syndrome. *Am J Gastroenterol* 2006;101:1581-90.
36. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. *Neurogastroenterol Motil* 2005;17:687-96.
37. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. *Aliment Pharmacol Ther* 2005;22: 387-94.
38. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of *Lactobacillus reuteri* ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study. *Clin Nutr* 2005;24:925-31.
39. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thorforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther* 2003;17:895-904.
40. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic *E. coli* preparation (DSM17252) compared to placebo. *Z Gastroenterol* 2009;47:209-14.
41. Enck P, Zimmermann K, Menke G, Müller-Lissner S, Martens U, Klosterhalfen S. A mixture of *Escherichia coli* (DSM 17252) and *Enterococcus faecalis* (DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians. *Neurogastroenterol Motil* 2008;20:1103-9.
42. Kajander K, Krogius-Kurikka L, Rinttilä T, Karjalainen H, Palva A, Korpela R. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. *Aliment Pharmacol Ther* 2007;26:463-73.
43. Moon JT, Kim HS, Park HJ. Effects of probiotics on the intestinal gas volume score and symptoms in patients with irritable bowel syndrome. A randomized double-blind placebo-controlled study. *Gastroenterology* 2007;132:A688.
44. Enck P, Menke G, Zimmermann K, Martens U, Klosterhalfen S. Effective probiotic therapy of the irritable bowel syndrome (IBS): A multi-center clinical trial with primary care physicians. *Gastroenterology* 2007;132:A79.
45. Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A randomized controlled trial of the probiotic combination Lactibiane® in irritable bowel syndrome, the Lactibiane® Study Group. *Gastroenterology* 2007;132:A371.
46. Simren M, Lindh A, Sammelsson L, Olsson J, Posserud I, Strid H, et al. Effect of yoghurt containing three probiotic bacteria in patients with irritable bowel syndrome (IBS) - A randomized, double-blind, controlled trial. *Gastroenterology* 2007;132:A210.
47. Kajander K, Korpela R. Clinical studies on alleviating the symptoms of irritable bowel syndrome. *Asia Pac J Clin Nutr* 2006;15: 576-80.
48. Simren M, Syrous A, Lindh A, Abrahamsson H. Effects of *Lactobacillus plantarum* 299v on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS) - A randomized, double-blind controlled trial. *Gastroenterology* 2006;130:A600.
49. Saggiore A. Probiotics in the treatment of irritable bowel syndrome (erratum in: *J Clin Gastroenterol* 2005;39:261). *J Clin Gastroenterol* 2004;38:S104-6.
50. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of *Lactobacillus plantarum* 299V in patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2001;13:1143-7.
51. Gade J, Thorn P. Paragurt for patients with irritable bowel syndrome. A controlled trial investigation from general practice. *Scand J Prim Health Care* 1989;7:23-6.
52. Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome. Double blind trial of *Saccharomyces boulardii*. *Medecine Chirurgie Digestives* 1983;12:77-9.
53. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. *Neurogastroenterol Motil* 2012;24:521-30.
54. Chassard C, Dapigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. *Aliment Pharmacol Ther* 2012;35:828-38.
55. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut* 2012;61:997-1006.
56. Kassinen A, Krogius-Kurikka L, Mäkituokko H, Tinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. *Gastroenterology* 2007;133:24-33.
57. Malinen E, Rinttilä T, Kajander K, Mätö J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real time PCR. *Am J Gastroenterol* 2005;100:373-82.
58. Arebi N, Gurmany S, Bullas D, Hobson A, Stagg A, Kamm M. Review article: the psychoneuroimmunology of irritable bowel syndrome – An exploration of interactions between psychological, neurological and immunological observations. *Aliment Pharmacol Ther* 2008; 28:830-40.
59. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. *Am J Gastroenterol* 2008;103:1557-67.
60. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. *Best Pract Res Clin Gastroenterol* 2003;17:725-40.
61. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004;126:693-702.

62. Dinan TG, Quigley EMM, Ahmed SMM, Scully P, O'Brien S, O'Mahony L. Hypothalamic-Pituitary-Gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? *Gastroenterology* 2006;130:304-11.
63. Kellow JE, Azpiroz F, Delvaux M, Gebhart GF, Mertz HR, Quigley EMM. Applied principles of neurogastroenterology: Physiology/motility sensation. *Gastroenterology* 2006;130:1412-20.
64. Shanahan F. Irritable bowel syndrome: shifting the focus toward the gut microbiota. *Gastroenterology* 2007;133:340-52.
65. Barrett JS, Canale KE, Geary RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. *World J Gastroenterol* 2008;14:5020-4.
66. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2005;3:237-47.
67. Mearin F, Baró E, Roset M, Badía X, Zárate N, Pérez I. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. *Am J Gastroenterol* 2003;99:113-21.
68. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, et al. Design of treatment trials for functional gastrointestinal disorders. *Gastroenterology* 2006;130:1538-51.
69. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorders. *Gastroenterology* 2006; 130:1480-91.
70. Mearin F, Roset M, Badía X, Balboa A, Baró E, Ponce J. Splitting irritable bowel syndrome: from original Rome to Rome II criteria. *Am J Gastroenterol* 2003;99:122-30.
71. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome – Focus on lactic acid bacteria. *Aliment Pharmacol Ther* 2012;35:403-13.
72. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. *Aliment Pharmacol Ther* 2008;28:385-96.
73. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. *J Clin Gastroenterol* 2012;46:220-7.

